Latest News from elva pharma

Merus Labs appoints two senior executives

July 3, 2016 – Merus Labs International (NASDAQ:MSLI; TSX:MSL) has appointed two key additions to its executive leadership team, effective July 1. Dr. Michael Bumby was named CFO, succeeding Andrew Patient, who has decided to leave the company to pursue other...

The launch of our brand new website

June 16, 2016 – elva pharma is pleased to announce the release of our new website, designed with a fresh new look and user-friendly navigation, updated with the latest information about our products and services. We hope you will enjoy our new site. If you have...

Merus reaches agreement to acquire three cardiovascular products

February 1, 2016 – Merus Labs International Inc. (“Merus” or the “Company”) [TSX: MSL, NASDAQ: MSLI] announced today that it has entered into an agreement with UCB to acquire rights to Elantan®, Isoket® and Deponit® in Europe and select other markets (the...


elva pharma s.r.o., Dr. Janského 599, 252 28 Černošice, Czech Republic,
+420 725 469 468,